All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Mutation testing in AML:
What you need to know
with Charles Craddock, Ralph Hills, and Gail Roboz
Wednesday, April 23, 2025
17:30-18:30 BST
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through a grant from Bristol Myers Squibb and Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
MRD as predictor of late relapses after transplant in AML or MDS/AML
Bookmark this article
|
Allo-HCT offers an important curative-intent treatment option for adult patients with AML following chemotherapy-induced remission.1 Pre-HCT MRD testing identifies patients with AML at high risk of relapse, which often occurs early post-HCT.1 To investigate the role of MRD testing in predicting later relapses, Ali et al.1 conducted a retrospective study in 935 patients with AML or MDS/AML who underwent HCT in first or second CR, with bone marrow restaging between Day +70 and +100, and who remained alive and relapse-free by Day +100. Their findings were published in Blood Advances.1 |
| Key learnings |
| 15% of patients were MRD+ pre-HCT, whilst only 1% were MRD+ at Day 70–100 post-HCT. Among patients alive without relapse at Day +100, MRD is uncommon but identifies patients at increased risk of relapse and reduced survival. |
| Patients who were MRD+ pre-HCT had a significantly higher risk of relapse and lower RFS and OS vs those who were MRD− (all p < 0.001), with no significant difference in NRM (p = 0.32 and p = 0.43, respectively). |
| Although 92% of pre-HCT MRD+ patients converted to MRD− at Day 70–100 post-HCT, 3-year outcomes were significantly worse than patients MRD− pre- and post-HCT, with relapse risk of 40% vs 15% (p < 0.001), RFS of 50% vs 72% (p < 0.001), and OS of 56% vs 76% (p < 0.001). |
| The results highlight the need for post-HCT pre-emptive therapies for patients with pre-HCT MRD. Further studies are needed to evaluate the potential of peri-HCT “MRD conversion” as a surrogate endpoint in clinical trials. |
Abbreviations: allo-HCT, allogeneic hematopoietic cell transplantation; AML, acute myeloid leukemia; CR, complete remission; HCT, hematopoietic cell transplantation; MDS, myelodysplastic syndromes; MRD, measurable residual disease; NRM, non-relapse mortality; OS, overall survival; RFS, relapse-free survival.
- Ali N, Othus M, Rodríguez-Arbolí E, et al. Measurable residual disease as predictor of post-day +100 relapses after allografting in adult AML. Blood Adv. 2025;9(3):558-570. DOI: 1182/bloodadvances.2024013214
More about...
Your opinion matters
2 votes - 23 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox